Thanks for the info and reference Fortuno! That i
Post# of 151876
So, if I understand these agreements correctly we will owe 'up to' 12.5% of net sales. How is the 'up to' determined? If there is no cap to the sales amount, ABBV and PGNX may end up making more from leronlimab than CytoDyn??
I hope I am not familiar enough with these agreements and misunderstanding something.

